Continuing Education Activity

Pretransfusion testing is a critical component of safe transfusion practice, covering every step from the clinician's order for blood products to the final verification and delivery of units at the patient’s bedside. This process includes essential laboratory procedures such as ABO and Rh blood typing, antibody screening, and compatibility testing, all aimed at preventing adverse reactions and ensuring patient safety. The activity also emphasizes the importance of patient identification, sample integrity, and accurate product labeling to reduce the risk of human error. In addition, it examines the growing role of electronic crossmatch systems and strategies for selecting appropriate red blood cell units in complex clinical situations in which compatible units are limited. By integrating serological and technological advances, pretransfusion testing enhances the reliability and efficiency of modern transfusion medicine.

Through this educational course, the participant gains a comprehensive understanding of the principles and practices that underpin safe blood transfusion. Knowledge of the testing process enhances awareness of how precision and communication directly influence patient outcomes. The course encourages collaboration among primary clinicians, nurses, and laboratory professionals, promoting a shared responsibility for transfusion safety. This interprofessional approach fosters clear communication during every stage, from specimen collection to bedside verification, reducing errors and ensuring evidence-based decision-making. As competence and teamwork improve, the healthcare system becomes better equipped to prevent transfusion-related complications, streamline patient care, and deliver more effective, coordinated treatment.

Objectives:

• Apply evidence-based principles to accurately perform and monitor each step in the pretransfusion testing process, from patient identification to final blood product issuance.
• Differentiate between the key laboratory methods used in pretransfusion compatibility testing, including antibody screening, crossmatching, and electronic crossmatch.
• Evaluate potential sources of error in pretransfusion testing and implement corrective actions to enhance transfusion safety.
• Collaborate effectively among primary care clinicians, nurses, and laboratory personnel to ensure communication and coordination throughout the transfusion chain for optimal patient outcomes.

Access free multiple choice questions on this topic.

Introduction

Pretransfusion testing is a multistep process that begins with the clinician’s order for the appropriate blood product and dose for the patient. Pretransfusion testing includes positive patient identification, collection of the patient’s blood sample for compatibility testing, determination of ABO and Rh blood groups for both the patient and the donor unit, and antibody screening of the patient’s serum or plasma. Following this, an appropriate blood component is selected, and compatibility testing, called cross-matching, is performed. Once compatibility is confirmed, the blood unit is labeled with complete product and patient identification details, and a compatibility report is generated to accompany the blood product during transfusion.

The overall purpose of pretransfusion testing is to ensure patient safety by confirming accurate patient identification, noting any special transfusion requirements, reviewing the patient’s transfusion history and antibody records, performing antibody screening and identification, and selecting appropriate, compatible blood units for transfusion.[1]

Red blood cells have antigenic proteins and carbohydrates on the cell surface. These epitopes are classified into blood groups based on structure and similarities to a parent protein. Patients lacking certain epitopes may develop antibodies upon exposure to these antigens via pregnancy, transfusion, or transplantation. These red cell alloantibodies can then target and destroy transfused red cells that carry the corresponding antigens.[2]

Transfusion and pregnancy are the primary means of sensitization to red cell antigens. In the general population, 2% to 4% of individuals possess irregular red cell alloantibodies. These antibodies can cause hemolytic disease in the newborn or hemolysis of the donor's transfused red cells.[3][4] If time permits, pretransfusion testing can identify the antibodies and provide antigen-negative units. 

In a "type and screen" procedure, the patient's red cells are typed for ABO and Rh (also known as D), and the patient's plasma is tested for clinically significant red cell antibodies.

A "type and crossmatch" involves selecting, matching, and reserving appropriate red cell components for the transfusion recipient. Many facilities have a maximum surgical blood ordering schedule that specifies when a type and screen is ordered and how many components should be reserved for each surgical procedure type. Red cell antibodies of clinical significance are produced in response to pregnancy or transfusion; they can cause hemolysis or shortened survival of transfused red cells carrying the corresponding antigen (ie, acute or delayed hemolytic transfusion reaction).

For this reason, the recipient's plasma is tested for the presence of these unexpected antibodies before red cell transfusion. If a patient has a clinically significant antibody, the transfusion service selects and reserves the appropriate red cell components that do not carry the corresponding antigen. Identifying a patient's red blood cell antibodies and cross-matching them with appropriate red blood cell units can take hours or even days, depending on the antibodies involved. This can be particularly problematic if the intended recipient has autoantibodies.[5] The various pretransfusion testing schemes are summarized in Table 1.

Table

Table 1. Pretransfusion testing schemes.

Specimen Requirements and Procedure

Routine testing of blood components before transfusion includes receiving an appropriately labeled patient sample from the transfusion service, testing for ABO and Rh D, screening for unexpected antibodies, and cross-matching red blood cell components with the patient sample.

Positive Patient Identification

To ensure safe blood transfusion, a properly labeled blood sample for pretransfusion testing must be collected from the correct patient. The person collecting the sample must verify the patient's identity using the wristband, which contains 2 unique patient identifiers (usually the patient's full name and the hospital's unique registration number) and remains on the patient throughout the hospital stay and blood transfusion. The information on the requisition form must be compared with that on the wristband; blood samples should not be collected if there is a discrepancy.[6]

The request form, either in paper or electronic form, for a transfusion must contain the following information:

• The patient's full name, including first and last (family and given), and sex
• A unique identifier, like a date of birth or a hospital or health card number
• The recipient's address
• The required blood component/product with the appropriate dose/volume
• The indication for transfusion
• History of previous transfusion or transfusion reactions
• Date and time of the order
• Identity of the qualified medical person ordering the blood products
• Date and time of the intended transfusion
• If any special requirements, like CMV-negative unit, leukoreduced, irradiated, washed, or reduced volume

Blood Sample

Pretransfusion testing requires a serum sample from the recipient's clotted blood and an EDTA sample for red blood cells and plasma. Hemolyzed or lipemic samples are unacceptable because they make it difficult to visualize agglutination, the endpoint of pretransfusion testing. Institutional policies determine how far in advance a sample can be collected. For patients with negative antibody screening and no history of transfusion or pregnancy in the previous 3 months, samples can be collected up to 1 month before surgery. However, if the patient has been transfused or pregnant in the prior 3 months, or if this history is uncertain, a pretransfusion sample is valid for only 3 days. For most hospitalized patients, a fresh sample must be taken every 3 days.[7] It is advisable to collect a clotted sample from the mother for pretransfusion testing in infants under 4 months of age.

The blood sample label should contain the following information:

1. Patient's full first and last names
2. Patient's health care record number
3. Date and time of specimen collection
4. Initials (if collected by laboratory personnel) or signature (if collected by nonlaboratory personnel) of a phlebotomist,
5. Possibly a unique blood bank number (found on a special blood bank identification band)

Samples not complying with the above information should be rejected, except for minor inconsistencies, such as spelling mistakes in the last name or the use of a short form of a full name, like 'Jon' for 'Jonathan'. Strict adherence to the specimen-labeling policy decreases the error rate in reporting the patient's blood group. Accurate specimen labeling is critical in transfusion medicine, where misidentification can lead to the administration of incompatible blood components, resulting in fatal acute hemolytic transfusion reactions. Specimens are to be labeled immediately after being drawn at the patient's bedside.[8]

Table

Table 2. Blood product selection compatibility chart.

Diagnostic Tests

Pretransfusion testing primarily relies on serological methods, with molecular techniques used only in select cases. Common serological approaches include test tube methods, column agglutination, and solid-phase assays. These techniques are based on detecting antigen-antibody reactions, which are observed as agglutination or hemolysis in vitro.

A critical component of testing is the antihuman globulin phase, which identifies red cell antibodies, typically immunoglobulin G, that do not directly agglutinate. Antihuman globulin reagents, usually immunoglobulin M antibodies, bind to the Fc portion of these immunoglobulin G molecules, linking red cells into a microscopically detectable lattice.[7] This process enhances the sensitivity of antibody detection and supports safe transfusion practices.

Testing Procedures

ABO and Rh Typing

The patient's ABO grouping is performed by assessing concordance between cell typing (forward grouping) and serum testing (reverse typing). Discrepancies noted, if any, should be resolved before proceeding with further pretransfusion testing. If an urgent blood requirement arises, an O group unit should be selected for cross-matching. Before finalizing the ABO typing report, testing must be performed on 2 samples collected separately at different times. RhD typing is performed by testing the recipient's red cells with anti-D sera. Weak D testing is not required in the RhD-negative samples unless the recipient is a neonate born to a RhD-negative mother.[6]

Antibody Screening

These are serological tests that detect clinically significant antibodies to blood group antigens via an indirect antiglobulin test. The recipient serum or plasma is incubated with a panel of red cells; usually, 2, 3, or 4 (unpooled) cells with a known blood group antigen profile are used for antibody screening. 

Antibody Identification

If the screening is positive, the next step is to determine antibody specificity using an extended panel of unpooled reagent red blood cells (11-20-cell panel). The method includes testing samples against a sufficient number of reagent red cells that lack or express a particular blood group antigen. The specificity of the antibody is determined by its reactivity pattern against the cell panel. Then, the probability calculation is performed, allowing a minimum p-value requirement of 0.05 for the antibody/antibodies. Additional testing strategies may be required, namely the use of enhancement media (albumin, polyethylene glycol, low-ionic-strength solution) or chemical/enzyme treatment of the panel cells to aid identification.

Antigen phenotyping: When an antibody is identified in a patient, the recipient can be phenotyped for the corresponding antigen to confirm that they are negative. Antigen phenotyping should also be performed on donor units to select negative units for the patient-identified antibody or to provide phenotype-matched blood, as in thalassemia or pregnancy. The phenotyping method is similar to forward typing and employs specific antisera. In patients who have recently received red blood cell transfusions, in which circulating transfusion products interfere with phenotyping, or for whom commercial antisera are unavailable, as in Dombrock, molecular genotyping may be used to ascertain the phenotype.[9]

Compatibility Testing

1. Immediate spin method: The recipient's serum/plasma is mixed with donor cells suspended in saline (major crossmatch) and vice versa (minor crossmatch) at room temperature. Immediate spin can be the only crossmatch method when the recipient lacks current or previously detected clinically significant antibodies.[6]
2. Antiglobulin crossmatch: In the liquid-phase (tube) method, donor unit red blood cells suspended in 2% to 5% saline are mixed with recipient serum, incubated at 37°C for approximately 45 minutes, and then washed to remove unbound antibodies. The antihuman globulin serum is added to the remaining cell button after washing, centrifuging, and agglutination reading. This can also be done using column agglutination or solid-phase systems.
3. Computer/electronic crossmatch: In this method, the patient is screened for antibodies and entered into the electronic system, which contains all available donor units along with their phenotype reports. The system selects compatible units for the patient from the inventory and displays them, allowing the computer to verify compatibility. Electronic crossmatch can be used as the sole method only after ensuring that the recipient has no clinically significant antibodies present historically or currently. However, validation is to be conducted on-site. The system should recognize and correlate anti­ body detection results, compare previous records, concor­dant ABO on the recipient from at least 2 determinations, donor component and unit number, and ABO/Rh retype results, as well as have logic to alert the user to discrepancies between donor unit labeling and confirmatory test interpretation, and ABO incompatibilities between the recipient and the donor unit.[10]

Interfering Factors

Several factors can affect the accuracy of pretransfusion testing, potentially leading to false-positive or false-negative results.[11]

False-positive results may occur due to:

• Rouleaux formation
• Passively transferred antibodies from platelet transfusions or intravenous immunoglobulin administration
• Antibodies reacting with preservatives present in testing reagents

False-negative results can result from:

• Technical errors or failure to add reagents
• Antibodies exhibiting a dosage effect that do not react when donor cells express a heterozygous antigen
• Loss of reagent potency
• Equipment malfunction
• Massive transfusion, which can dilute the patient’s blood and alter the apparent blood type or antibody profile, depending on the ABO type of the red cells and plasma used during emergency resuscitation

To ensure accuracy, blood products should continue to be guided by pre-transfusion samples whenever possible.

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma:

Anti-CD38 antibodies, such as daratumumab, interfere with pre-transfusion testing by binding to CD38 on red blood cells (RBCs), resulting in false-positive reactions. This can be analogous to panagglutination in tests such as the indirect antiglobulin test (IAT). This can mask true clinically significant alloantibodies, delaying transfusions and increasing the risk of reactions. To overcome this, laboratories use methods such as dithiothreitol (DTT) treatment to remove anti-CD38 antibodies from patient and donor cells before testing; however, this can denature other antigens, such as Kell, requiring further precautions.[12]

Results, Reporting, and Critical Findings

 Table 3:

Table

Compatibility testing Incompatible Saline Crossmatch

Interpretation 

A positive antibody screen indicates the presence of an antibody; further identification is required to determine its specificity and clinical significance. In pregnant patients, detected alloantibodies are typically evaluated with a titer test to monitor potential fetal risk. A negative result indicates that no antibodies were detected.

When a positive antibody screen coincides with an incompatible crossmatch and a negative auto-control, this suggests the presence of alloantibody(s). A positive auto-control may result from nonspecific antibodies against the enhancement medium or from rouleau formation.

Crossmatching by indirect antiglobulin testing: A negative result (crossmatch compatible) indicates that the patient’s serum or plasma contains no detectable antibodies reactive with the donor red cells.

Compatibility testing in infants (<4 months of age): Crossmatch compatibility is not required if the antibody screen is negative and transfused red cells are ABO identical, compatible, or group O and RhD negative or identical. Testing should also utilize maternal serum or plasma.[13] Evidence supports the use of fresher red cells (less than 7 days old) for transfusions exceeding 25 ml/kg in neonates.[14]

Emergency release: In urgent situations where the recipient’s blood type is unknown, uncrossmatched ABO-identical red cells, group O red cells, or group O whole blood (without hemolysins) may be issued. Compatibility testing should continue, and any detected incompatibility must be communicated to the recipient’s primary care clinician immediately.[15]

Clinical Significance

In emergencies and before crossmatch-compatible blood components are available, group O red cells and group AB plasma (or group A plasma, as some facilities use) can be transfused appropriately. A properly labeled blood sample from the intended recipient, collected before transfusion, is critical to the safety of blood transfusion. Most hemolytic transfusion reactions are caused by misidentification of the patient or labeling errors of blood samples.

Selection of Appropriate Red Cell Units

Recipients should receive ABO- and RhD-identical or compatible units unless warranted. In situations where RhD-negative units are unavailable, RhD-positive units may be given to men and women of reproductive age after they have been determined to lack anti-D antibodies. Fresh red cell units (less than 7 days old) should be selected for large-volume transfusions (>25 ml/kg) in neonates.[14]

Selection of Other Blood Products

All plasma-containing components should be compatible with the recipient's red cells. All products containing more than 2 ml of red cells must be ABO compatible with the recipient's plasma. When RhD-positive products are given to RhD-negative recipients, RhIg should be administered.

Quality Control and Lab Safety

Quality assurance is a cornerstone of safe transfusion practices and essential for maintaining the accuracy, reliability, and traceability of pretransfusion testing. Blood banks and transfusion laboratories must establish a comprehensive quality assurance mechanism that covers all aspects of personnel competency, equipment, reagents, and testing processes.[16] A robust quality assurance system begins with well-trained personnel. Continuous education, training, and competency assessments must be carried out at defined intervals to ensure that all staff performing blood grouping, antibody screening, and cross-matching are proficient and adhere strictly to standard operating procedures.[11]

It is essential to identify the critical steps in pretransfusion testing and establish checkpoints to minimize the risk of errors throughout the process, from sample collection and labeling to final result verification. Such checkpoints serve as quality gates, ensuring that deviations are promptly detected and addressed before patient results are released.[17] In addition to staff competency, internal quality control is integral to daily operations. Internal quality control must be performed on all reagents and testing systems, including antisera, screening cells, and antiglobulin reagents, to verify their expected performance before patient testing begins. If internal quality control results fall outside the acceptable range, corrective and preventive actions must be initiated immediately. No patient testing should be performed or reported until the issue is resolved and control results return within the desired range. Only after satisfactory internal quality control performance is confirmed should routine testing be resumed.[18][19]

Furthermore, participation in external quality assessment or proficiency testing programs, such as those offered by the College of American Pathologists or other recognized bodies, is mandatory. These programs provide an objective evaluation of laboratory performance, help identify systemic errors, and promote continuous improvement through inter-laboratory comparison.[20] The reagents used in pretransfusion testing, including antisera, screening and panel cells, and antihuman globulin reagents, must undergo performance verification and lot-to-lot verification before use. All reagents must meet the quality criteria established by regulatory authorities and accreditation bodies to ensure consistency, sensitivity, and specificity. Verification results must be documented for traceability and audit purposes.[10]

Overall, a well-structured quality assurance program ensures that pretransfusion testing remains accurate, consistent, and compliant with international standards, such as those set by the American Association of Blood Banks, the College of American Pathologists, and ISO 15189. This systematic approach minimizes the risk of transfusion errors, enhances patient safety, and strengthens laboratory credibility. Universal precautions must be strictly observed during all phases of pretransfusion testing, as laboratory personnel routinely handle potentially infectious blood and body fluid specimens. To minimize the risk of infection and ensure staff safety, all samples, reagents, and contaminated materials must be treated as biohazardous and disposed of in accordance with established biomedical waste management guidelines.[21]

Laboratory safety in the transfusion service is maintained through regular, structured staff training to reinforce biosafety awareness specific to blood bank operations. Consistent use of appropriate personal protective equipment, such as gloves, lab coats, and face shields, is mandatory when performing activities such as blood grouping, antibody screening, and crossmatching.[22] Personnel must strictly adhere to safe work practices to prevent contamination and accidental exposure, including avoiding mouth pipetting, minimizing aerosol generation, and maintaining clean, organized work surfaces. Any accidents, injuries, or potential exposures must be reported immediately to enable prompt medical evaluation and corrective action. A clearly defined and accessible protocol should be established for managing blood spills in the testing area, including appropriate disinfection procedures and waste disposal.[23] 

Furthermore, all technical staff involved in pretransfusion testing must receive Hepatitis B vaccination and prophylaxis as part of the institutional occupational health and safety program. Collectively, these measures foster a culture of safety within the transfusion laboratory, ensuring biosafety compliance and protecting both laboratory personnel and patients from preventable risks.[24]

Enhancing Healthcare Team Outcomes

Ensuring that the correct blood reaches the right patient requires coordinated teamwork among clinicians, nurses, and laboratory personnel. Transfusion medicine specialists play a key role in designing and maintaining an efficient transfusion process within the hospital. From the attending clinician’s decision to transfuse to the bedside administration of blood products, every member of the medical team is essential. This includes the phlebotomist who collects the patient sample, laboratory staff who perform testing, personnel who prepare and transport the blood to the transfusion site, whether a ward or operating room, and the nurses who administer and monitor the transfusion. Each link in this chain is critical to patient safety.

Transfusion medicine staff work with primary care clinicians to implement patient blood management and the rational use of blood products. They oversee blood donation, pretransfusion testing for compatibility and for blood group antigens and antibodies, and the selection of blood for patients undergoing transplantation. Therapeutically, they handle transfusion reactions, plasmapheresis, exchange transfusions, and peripheral stem cell collections. Transfusion clinicians manage and support clinical transfusion therapy, which may require modified blood products, such as intrauterine transfusions and blood product exchanges. Transfusion laboratories implement key quality-assurance systems to ensure safe, high-quality blood products. Transfusion medicine is highly complex, with many opportunities for redundancy. Designing transfusion medicine processes with human factors in mind reduces the possibility of errors. Creating causal trees provides a realistic view of how a system works and facilitates the development of effective and durable solutions.

Given the significant impact of blood administration, transfusion medicine has become a leader in healthcare safety innovation. Over many years, numerous clinical hazards have been reduced or eliminated. While many steps in the transfusion process remain largely manual and procedural, awareness of these vulnerabilities has driven greater focus on improving the overall transfusion process. A notable example of this progress is the development of the Transfusion Safety Officer role in hospitals, created to monitor, identify, and address factors that could compromise patient safety during transfusion.

Safety in transfusion medicine has evolved from an exclusive focus on disease transmission and clinical outcomes to an emphasis on error-prone processes. Knowledge of the key steps in pretransfusion testing and the critical points in the process flow helps strengthen the transfusion chain.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Boisen ML, Collins RA, Yazer MH, Waters JH. Pretransfusion testing and transfusion of uncrossmatched erythrocytes. Anesthesiology. 2015 Jan;122(1):191-5. [PubMed: 25127209]

2.

Lomas-Francis C, Westhoff CM. Red Cell Antigens and Antibodies. Hematol Oncol Clin North Am. 2022 Apr;36(2):283-291. [PubMed: 35282947]

3.

Yu Y, Wang Y, Sun XL, Ma CY, Zhang XJ, Guan XZ, Chen LF, Wang DQ. Prevalence and Specificity of Red Blood Cell Alloantibodies in Patients from China During 1994-2013. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1734-41. [PubMed: 26708902]

4.

Das S, Shastry S, Rai L, Baliga PB. Frequency and clinical significance of red cell antibodies in pregnancy - A prospective study from India. Indian J Pathol Microbiol. 2020 Apr-Jun;63(2):241-246. [PubMed: 32317523]

5.

Boral LI, Hill SS, Apollon CJ, Folland A. The type and antibody screen, revisited. Am J Clin Pathol. 1979 May;71(5):578-81. [PubMed: 110134]

6.

Evanovitch D. A primer in pretransfusion testing. Transfus Apher Sci. 2012 Jun;46(3):281-6. [PubMed: 22503306]

7.

Alquist CR, Helander L. Transfusion Blood Bank (Recipient) Testing. Clin Lab Med. 2021 Dec;41(4):599-610. [PubMed: 34689967]

8.

Lumadue JA, Boyd JS, Ness PM. Adherence to a strict specimen-labeling policy decreases the incidence of erroneous blood grouping of blood bank specimens. Transfusion. 1997 Nov-Dec;37(11-12):1169-72. [PubMed: 9426641]

9.

Westhoff CM. Blood group genotyping. Blood. 2019 Apr 25;133(17):1814-1820. [PubMed: 30808639]

10.

Wang SS, Zhang H, Qu L, Zhao Z, Li L. A renewed understanding of anti-human globulin reagents: interference constraints using an optimization method in pretransfusion compatibility tests. J Clin Lab Anal. 2021 Mar;35(3):e23695. [PMC free article: PMC7957968] [PubMed: 33543811]

11.

Andıç N. Practical Solutions for Problems in Blood Grouping and Crossmatching. Turk J Haematol. 2022 Feb 23;39(1):55-60. [PMC free article: PMC8886265] [PubMed: 34886658]

12.

Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Miles Prince H, Mollee P, Spencer A, Joy Ho P, Harrison SJ, Lee C, Augustson B, Daly J. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J. 2018 Feb;48(2):210-220. [PubMed: 29415351]

13.

Arora S, Dua S, Goel R. Neonatal and pediatric transfusion practices and policies in India: A survey-based cross-sectional assessment of blood centers. Transfusion. 2022 May;62(5):1000-1009. [PubMed: 35357016]

14.

Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion. 2000 Dec;40(12):1528-40. [PubMed: 11134575]

15.

Guidelines for compatibility testing in hospital blood banks. A joint publication of the British Society for Haematology and the British Blood Transfusion Society. Clin Lab Haematol. 1987;9(3):333-41. [PubMed: 3652645]

16.

Chevrolle F. [Quality assurance in blood transfusion]. Ann Pharm Fr. 2002 Sep;60(5):318-25. [PubMed: 12378141]

17.

Sidhu M, Meenia R, Akhter N, Sawhney V, Irm Y. Report on errors in pretransfusion testing from a tertiary care center: A step toward transfusion safety. Asian J Transfus Sci. 2016 Jan-Jun;10(1):48-52. [PMC free article: PMC4782493] [PubMed: 27011670]

18.

Xu GP, Wu LF, Li JJ, Gao Q, Liu ZD, Kang QH, Hou YJ, Zhang LC, Hu XM, Li J, Zhang J. Performance Assessment of Internal Quality Control (IQC) Products in Blood Transfusion Compatibility Testing in China. PLoS One. 2015;10(10):e0141145. [PMC free article: PMC4619478] [PubMed: 26488582]

19.

Yu Y, Ma C, Feng Q, Chen X, Guan X, Zhang X, Chen L, Lin Z, Pan J, Zhang T, Luo Q, Wang D. Establishment and performance assessment of preparation technology of internal quality control products for blood transfusion compatibility testing. Exp Ther Med. 2013 May;5(5):1466-1470. [PMC free article: PMC3671829] [PubMed: 23737900]

20.

Montalvão SAL, Lowe A, Kitchen S. Advantages of external quality assessment-EQA programs. Haemophilia. 2022 Jul;28(4):679-686. [PubMed: 35415926]

21.

Kopitnik NL, Kahwaji CI. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 2, 2025. Universal Precautions. [PubMed: 29262198]

22.

Kening MZ, Groen K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 22, 2023. Personal Protective Equipment. [PubMed: 36943957]

23.

Vijayan V, Sern BNB, Johnson B. Modified Efficient and Simple Method for Biological Spill Cleanup. Appl Biosaf. 2019 Sep 01;24(3):141-146. [PMC free article: PMC9134464] [PubMed: 36032338]

24.

Asiry S, Ang LC. Laboratory Safety: Chemical and Physical Hazards. Methods Mol Biol. 2019;1897:243-252. [PubMed: 30539449]

Disclosure: Abhishekh Basavarajegowda declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Zubair declares no relevant financial relationships with ineligible companies.

Disclosure: Shamee Shastry declares no relevant financial relationships with ineligible companies.